Related Experiment Video

Updated: May 7, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Apelin and its receptor APJ in cardiovascular diseases

Xiao-Hua Yu1, Zhi-Bin Tang2, Li-Jing Liu3

  • 1Life Science Research Center, University of South China, Hengyang, Hunan 421001, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|September 24, 2013
PubMed

Insights

The apelin/APJ system, a key regulator of cardiovascular homeostasis, offers therapeutic potential for heart diseases. Targeting this system shows promise in protecting against various cardiovascular conditions.

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Pharmacology

Background:

  • Apelin is an adipokine and the endogenous ligand for the APJ receptor.
  • The apelin/APJ system is widely expressed, particularly in the heart and vasculature.
  • This system plays a crucial role in cardiovascular homeostasis.

Purpose of the Study:

  • To review the role of the apelin/APJ system in cardiovascular diseases.
  • To explore the therapeutic potential of targeting the apelin/APJ axis.
  • To summarize recent data on apelin/APJ in major cardiovascular conditions.

Main Methods:

  • Literature review of recent studies on the apelin/APJ system.
  • Analysis of data concerning the cardiovascular actions of apelin and APJ.
  • Synthesis of information on therapeutic strategies targeting the apelin/APJ axis.

Main Results:

  • Apelin exhibits positive inotropic effects and promotes nitric oxide-dependent vasodilation.
  • The apelin/APJ system is implicated in the pathophysiology of cardiovascular diseases.
  • Targeting the apelin/APJ axis demonstrates protective effects against cardiovascular diseases.

Conclusions:

  • The apelin/APJ system is a critical mediator of cardiovascular health.
  • Understanding its cardiovascular actions can lead to novel therapeutic interventions.
  • Targeting the apelin/APJ axis holds significant therapeutic potential for cardiovascular diseases.

Keywords:
ABCA1ACAT1APJATP-binding cassette transporter A1Ang IIAng-1ApelinAtherosclerosisBMPBNPCADCOX-2FGF2GSKHDACHIF-1αHeart failureHypertensionICAM-1IRS1JNKMCP-1MEF2MIRINOPAHPDGF-BBPGE2PI3KPKBPKCPPAR response elementsPPREsTGF-βTNF-αVCAM-1VEGFAVSMCacyl coenzyme A:cholesterol acyltransferase-1angiopoietin-1angiotensin IIapo Eapolipoprotein Ebone morphogenic proteinbrain natriuretic peptidec-Jun N-terminal kinasecoronary heart diseasecyclooxygenase-2fibroblast growth factor 2glycogen synthase kinasehistone deacetylasehypoxia-inducible factor 1αinsulin receptor substrate 1intercellular adhesion molecule-1monocyte chemoattractant protein-1myocardial ischemia–reperfusion injurymyocyte enhancer factor 2nitric oxidephosphatidylinositol 3-kinaseplatelet-derived growth factor-BBprostaglandin E2protein kinase Bprotein kinase Cpulmonary arterial hypertensiontransforming growth factor-βtumor necrosis factor-αvascular cell adhesion molecule-1vascular endothelial growth factor type Avascular smooth muscle cell

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...